Journal article
The Safety and Efficacy of Second-Generation Basal Insulin Analogues in Adults with Type 2 Diabetes at Risk of Hypoglycemia and Use in Other Special Populations: A Narrative Review
Alice YY Cheng, Jencia Wong, Nick Freemantle, Shamasunder H Acharya, Elif Ekinci
DIABETES THERAPY | SPRINGER HEIDELBERG | Published : 2020
Abstract
Hypoglycemia is a major barrier impeding glycemic control in persons with type 2 diabetes mellitus and creates a substantial burden on the healthcare system. Certain populations that require special attention, such as older adults and individuals with renal impairment, a longer duration of diabetes or those who have experienced prior hypoglycemia, may be at a higher risk of hypoglycemia, particularly with insulin treatment. Second-generation basal insulin analogues (insulin glargine 300 U/mL and degludec) have demonstrated reductions in hypoglycemia compared with insulin glargine 100 U/mL although evidence of this benefit across specific populations is less clear. In this review we summarize..
View full abstractGrants
Funding Acknowledgements
This review received funding from Sanofi. Funding for medical writing support and the journal's rapid service fee was also provided by Sanofi. The funder had the following involvement with the review: funding support to Celia Green, Bioscript Pty Ltd, Australia, who provided literature research and medical writing support; funding for librarian support, with search terms provided by authors; manuscript review, with all final decisions on content determined by the authors.